Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4 - Wikidata - wikimedia - TriplyDB

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

http://www.wikidata.org/entity/Q28293310

about

Interaction of human cytochrome P4503A4 with ritonavir analogs Update of KDBI: Kinetic Data of Bio-molecular Interaction database.Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2.The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme.The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis.Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.The hungry stomach: physiology, disease, and drug development opportunities.Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Pharmacogenetics/genomics and personalized medicine.Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants.Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.Grapefruit-drug interactions: can interactions with drugs be avoided?Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.Inhibition of cytochromes p450: existing and new promising therapeutic targets.Application of mechanism-based CYP inhibition for predicting drug-drug interactions.Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression.Herb-drug pharmacokinetic interactions reviewed.The role of diet on the clinical pharmacology of oral antineoplastic agents.How is sesamin metabolised in the human liver to show its biological effects?Drug-vitamin D interactions: a systematic review of the literature Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs.Analysis of Mechanism-Based Inhibition of CYP 3A4 by a Series of Fluoroquinolone Antibacterial Agents.Effects of liver fibrosis on verapamil pharmacokinetics in rats.Identification and analysis of the reactive metabolites related to the hepatotoxicity of safrole.In vitro-in vivo extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure.Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model.Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model.Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.Interindividual variability in dabigatran and rivaroxaban exposure: contribution ofABCB1genetic polymorphisms and interaction with clarithromycin

P2860

Q27678008-D9D320E0-9753-4657-8967-D6687ADE5940 Q33381173-38464543-AB3B-428A-A33D-B6945CEC325E Q33613354-9FF709E1-B494-404B-B7ED-3810FF465989 Q34039772-95598D61-990B-4981-8C13-67D459D425B1 Q34076521-0AA8BA5B-B127-4FAE-A690-427B2D724AE1 Q34357861-F2E69696-E394-4716-85B2-0AF3AC6CE109 Q34589333-35DC7EE3-36C6-47B3-BB44-FAF5CA3B2A05 Q34645793-842DB541-2240-439A-B348-84E746BB7DB7 Q35015993-2DBA5B6C-6ABB-4FAB-AD56-A03514C257D9 Q35065871-69022C77-D7C9-43FB-92E1-8D4C5C30CF01 Q35215647-3B8DE600-8648-46FD-A8DF-AAB16C273333 Q36072448-2E357336-3BD2-4CE5-A5B7-444322AD9A68 Q36294685-5537F4C7-9095-4451-BCFE-1F5CF9A919A6 Q36535990-7BC93AE3-3CC3-4D70-965C-2B19EF3E5112 Q36558235-F70A5D69-9B13-4098-8B8D-D5C8DD6F15D2 Q36652594-DE601102-1646-4361-8AE7-620ED3157D64 Q36668891-F2A89929-3F1B-456F-AD6F-C57F2D455DBF Q36871056-CA10A785-0D5B-4151-B2F6-4915D0460E29 Q36929602-8E12E539-94B2-4F77-A9DF-93C58E670AEB Q37494640-F3D16687-8FF2-470B-ACC9-AB4E1E93FDDE Q37693956-82FC179C-305C-459C-9487-D8F09B56426C Q37808478-2D92C51B-1B4C-4B0B-BF67-58B9274A5ABD Q37907103-033331F4-D5FE-4963-AF16-BAF80E843F12 Q37958017-2D39087D-D17A-4283-963A-4B9211570EA8 Q38073239-87A3110B-5D53-4CBA-85A5-1DDFBE528FE3 Q38495022-011CBC6E-311F-4888-82F8-D8DBCE5B48A8 Q43333422-52D85D24-D180-4F20-A8A7-5F776B714573 Q46509647-3B036EA7-37D7-4332-8BDA-B14DD4A6AA1F Q46921383-356BB502-BEF6-468A-A465-7B4CA6A4F783 Q47693100-BB3C4476-0826-4F89-B23D-FC937EBF4B60 Q47760575-9B15EF30-8877-4110-82FE-1E4024DB185C Q48228997-82FF784F-8C67-4CD5-810F-ABD31E398872 Q49345918-5A865AA7-9C25-4C44-A4F6-FFF267824D33 Q51937078-45578A57-14D7-42A8-B194-58C8C954A385 Q52334679-AB51A6A8-E8DF-40A4-ADFE-95F76EAA283F Q57314038-19A36413-DFF4-44FA-B68F-3AF954C3BB45

P2860

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

http://www.wikidata.org/entity/Q28293310

description

2004 nî lūn-bûn

@nan

2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

@ast

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

@en

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

@nl

type

label

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

@ast

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

@en

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

@nl

prefLabel

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

@ast

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

@en

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

@nl

P1433

Q28293310-79B22B4C-D36A-461E-B1F5-486B6E3E818A

P1476

Q28293310-24A5D56C-B4E6-4669-8DEC-D305BC92A0E9

P2093

Q28293310-1751620E-D2B0-48C0-AB30-E29B045DFE6D

Q28293310-22547686-7E04-4A98-83BC-4F93C9784960

Q28293310-4DF4759B-9D3B-421A-8DEF-165862F3CDCF

Q28293310-50E3C7EB-E9D0-42C9-B08C-8524CC9AD66E

Q28293310-7CAD87E7-A64F-4D59-89AF-162B60E63EDF

Q28293310-B7C0734D-71DE-4E32-A1B8-E4BE21F2EF2D

Q28293310-D3934553-255F-4D55-9981-2DC5F0DFBE21

Q28293310-F12B49B6-FFBA-4D0F-8971-122583EAD68C

Q28293310-F517FE0F-6E92-4C86-92F7-E80BB7AF4AC1

P304

Q28293310-DD84B76C-0715-454D-B589-5F376A27D126

P31

Q28293310-F2D1FF2E-ED18-4A44-BE7A-0B93D8BDBDB8

P356

Q28293310-7FFA628A-1C39-434E-99F2-1022FD1623F1

P407

Q28293310-5352C802-AD50-4D2D-B83E-C7BA1CAAB3F9

P433

Q28293310-7A1427A5-8F74-4F44-BFA6-28146AE62F86

P478

Q28293310-CE376301-1F0F-4C25-8D69-B1CD2B503760

P577

Q28293310-C350596C-991A-4599-8E3F-811E2203A2CB

P698

Q28293310-B7E3ACD7-19DD-40F8-BB4B-7F0B9E8A532A

P356

1389200043335450

P1433

Current Drug Metabolism

P1476

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

@en

P2093

Anlong Xu

http://www.w3.org/2001/XMLSchema#string

Eli Chan

http://www.w3.org/2001/XMLSchema#string

Jiancheng Wang

http://www.w3.org/2001/XMLSchema#string

Lee Yong Lim

http://www.w3.org/2001/XMLSchema#string

Min Huang

http://www.w3.org/2001/XMLSchema#string

Qiang Zhang

http://www.w3.org/2001/XMLSchema#string

Shu Chuen Li

http://www.w3.org/2001/XMLSchema#string

Shufeng Zhou

http://www.w3.org/2001/XMLSchema#string

Urs A Boelsterli

http://www.w3.org/2001/XMLSchema#string

P304

415-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/1389200043335450

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2004-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15544435

http://www.w3.org/2001/XMLSchema#string